Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof

A. compound of formula I:

• wherein
• Z is a 5- or 6-membered substituted or unsubstituted aryl or substituted or unsubstituted heterocyclo ring,
• each of R1 and R2 is individually selected from the group consisting of hydrogen, halogen, an alkyl group, a substituted or unsubstituted aryl group containing 5 or 6 carbon atoms in the aryl ring;
• X is selected from
• each of R3 and R4 is individually selected from the group consisting of hydrogen, an alkyl group, or
• R3 and R4 may be combined to form a ring moiety;
• or
• R3 and R4 may be combined to form a carbonyl to give a ketone, ester or amide;
• or
• either R3 or R4 may be —OH, —O—R6 or —NH2, —NHR6, —NR6R7, —S—R6 with the proviso that an R3 or R4 does not place two groups selected from —OH, —O—R6 or —NH2, —NHR6, —NR6R7, —S—R6 on the same C atom;
• or
• R3 and R4 may be taken together to form a double or triple bond with the proviso that they are not substituted with a S(O)x, —NH2, —NH(R6),—N(R6R7)—, —OH or —O—R6 to give an enol, enolether, vinyl sulfone, vinylthioether, vinylsulfoxide, enamine;
• Y may be absent, may be hydrogen, may be substituted or unsubstituted aryl or substituted or unsubstituted heterocyclo group containing 4 to 7 atoms in the ring, or may be COR5, or S(O)xR5;
• and
• R5 is NH2, NHR6, NR6R7, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclo group containing 4 to 7 atoms in the ring;
• m is 1 or 2
• n is 1 to 5
• p is 0 to 3
• x is 0, 1 or 2
• each R6 and R7 is individually an alkyl group, an unsubstituted 5- or 6-membered saturated hydrocarbon ring;
• or a derivative thereof selected from the group consisting of pharmaceutically acceptable salts, prodrugs, deuterated forms, radio-actively labeled forms, isomers, solvates and combinations thereof.